South Korea facilitates the registration of rare disease drugs through an expedited approval process managed by the Ministry of Food and Drug Safety (MFDS). These drugs, often classified as orphan drugs, may receive regulatory support, fee reductions, and extended market exclusivity to encourage development and ensure timely access for patients with rare conditions.